Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sukhatme

Showing results (61-70 of 317) with videos related to

Pageof 32
Sort By:
FEBS Letters|June 9, 2012
Glycolytic cancer cells lacking 6-phosphogluconate dehydrogenase metabolize glucose to induce senescenceVikas P Sukhatme, Barden Chan
Ecancermedicalscience|March 3, 2015
Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agentAn Mt Van Nuffel, Vidula Sukhatme, Pan Pantziarka, et al.
The American Journal of Physiology|January 14, 1999
Gene transfer in the kidneyV R Kelley, V P Sukhatme
Dermatologic Therapy|February 19, 2009
Pediatric psoriasis: updates in biologic therapiesSmita V Sukhatme, Alice B Gottlieb
Physical Review. A, Atomic, Molecular, and Optical Physics|October 1, 1993
New exactly solvable Hamiltonians: Shape invariance and self-similarityBarclay, Dutt, Gangopadhyaya, et al.
Seminars in Nephrology|November 1, 1992
Molecular biology in nephrology: an overview with emphasis on the study of renal cancerH T Cohen, V P Sukhatme
Nucleic Acids Research|April 10, 1987
The major ras induced protein in NIH3T3 cells is cathepsin LL Joseph, S Lapid, V Sukhatme
Kidney International|March 13, 2003
A refined understanding of immunosuppressives and cancer riskTerry B Strom, Vikas P Sukhatme
Journal of Thrombosis and Haemostasis : JTH|March 8, 2005
Coley's toxin revisited: immunotherapy or plasminogen activator therapy of cancer?L R Zacharski, V P Sukhatme
Frontiers in Immunology|February 1, 2024
Readily available drugs and other interventions to potentially improve the efficacy of immune checkpoint blockade in cancerMerissa Coleman, Sophia J Mascialino, Anusha Panjwani, et al.
Pageof 32

Showing results (61-70 of 317) with videos related to

Sort By:
Pageof 32
FEBS Letters|June 9, 2012
Glycolytic cancer cells lacking 6-phosphogluconate dehydrogenase metabolize glucose to induce senescenceVikas P Sukhatme, Barden Chan
Ecancermedicalscience|March 3, 2015
Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agentAn Mt Van Nuffel, Vidula Sukhatme, Pan Pantziarka, et al.
The American Journal of Physiology|January 14, 1999
Gene transfer in the kidneyV R Kelley, V P Sukhatme
Dermatologic Therapy|February 19, 2009
Pediatric psoriasis: updates in biologic therapiesSmita V Sukhatme, Alice B Gottlieb
Physical Review. A, Atomic, Molecular, and Optical Physics|October 1, 1993
New exactly solvable Hamiltonians: Shape invariance and self-similarityBarclay, Dutt, Gangopadhyaya, et al.
Seminars in Nephrology|November 1, 1992
Molecular biology in nephrology: an overview with emphasis on the study of renal cancerH T Cohen, V P Sukhatme
Nucleic Acids Research|April 10, 1987
The major ras induced protein in NIH3T3 cells is cathepsin LL Joseph, S Lapid, V Sukhatme
Kidney International|March 13, 2003
A refined understanding of immunosuppressives and cancer riskTerry B Strom, Vikas P Sukhatme
Journal of Thrombosis and Haemostasis : JTH|March 8, 2005
Coley's toxin revisited: immunotherapy or plasminogen activator therapy of cancer?L R Zacharski, V P Sukhatme
Frontiers in Immunology|February 1, 2024
Readily available drugs and other interventions to potentially improve the efficacy of immune checkpoint blockade in cancerMerissa Coleman, Sophia J Mascialino, Anusha Panjwani, et al.
Pageof 32